Pentwater Capital Management LP bought a new stake in shares of Avanos Medical, Inc. (NYSE:AVNS - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 750,000 shares of the company's stock, valued at approximately $18,660,000. Pentwater Capital Management LP owned about 1.60% of Avanos Medical at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also modified their holdings of AVNS. EverSource Wealth Advisors LLC lifted its stake in Avanos Medical by 132.6% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,496 shares of the company's stock valued at $28,000 after buying an additional 1,423 shares in the last quarter. Russell Investments Group Ltd. raised its stake in Avanos Medical by 969.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company's stock valued at $31,000 after purchasing an additional 2,307 shares during the period. Wexford Capital LP purchased a new stake in shares of Avanos Medical in the third quarter worth approximately $70,000. Longfellow Investment Management Co. LLC acquired a new stake in shares of Avanos Medical during the second quarter worth approximately $75,000. Finally, Tower Research Capital LLC TRC grew its position in Avanos Medical by 433.0% during the second quarter. Tower Research Capital LLC TRC now owns 6,257 shares of the company's stock valued at $77,000 after purchasing an additional 5,083 shares in the last quarter. Institutional investors and hedge funds own 95.17% of the company's stock.
Analysts Set New Price Targets
A number of research firms recently issued reports on AVNS. Weiss Ratings reissued a "sell (d-)" rating on shares of Avanos Medical in a research report on Monday, July 20th. Zacks Research upgraded shares of Avanos Medical from a "strong sell" rating to a "hold" rating in a report on Friday, June 5th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Avanos Medical has an average rating of "Reduce".
Read Our Latest Stock Report on AVNS
Avanos Medical Price Performance
Shares of NYSE:AVNS opened at $24.99 on Thursday. Avanos Medical, Inc. has a 1-year low of $9.30 and a 1-year high of $25.49. The firm has a market capitalization of $1.17 billion, a PE ratio of -15.52 and a beta of 1.57. The business's 50 day moving average is $24.96 and its 200-day moving average is $21.30. The company has a current ratio of 2.48, a quick ratio of 1.40 and a debt-to-equity ratio of 0.11.
Avanos Medical Company Profile
(
Free Report)
Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company's products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.
In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.
Further Reading
Want to see what other hedge funds are holding AVNS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avanos Medical, Inc. (NYSE:AVNS - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Avanos Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avanos Medical wasn't on the list.
While Avanos Medical currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
